Trial | NCT03663634  Report issue

Title

Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin B
Cytochalasin B Supplementation to ICSI Handling Medium

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    987
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Cytochalasin B serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Cytochalasin B during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,
Study Started
Sep 16
2018
Primary Completion
Jul 20
2019
Study Completion
Aug 01
2019
Last Update
Aug 07
2019

Other Cytochalasin B use in ICSI handling medium

A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate

Handling Medium Supplemented with Cytochalasin B Experimental

Handling Medium as it is. No Intervention

Criteria 

Inclusion Criteria:

All ICSI candidates patients

Exclusion Criteria:

No exclusion
No Results Posted